YI-MING XU1,*, WEI LIU2,*, LI-HUA YAN, SHENG-GUANG DING, HAI-TAO HUANG, CHONG-JUN ZHONG
1Department of Thoracic and Cardiovascular Surgery, The Affiliated Hospital of Nantong University, Nantong 226001, China - 2Department of Thoracic Surgery, Haian people’s Hospital Affiliated to Nantong University, Nantong 226600, China
MicroRNAs (miRNAs) are endogenous small noncoding RNAs that play important roles in regulating cancers. We previously indicated that miR-222 promotes non-small cell lung cancer growth. Here, we aimed to investigate whether the miR-222 expression level was associated with clinic pathological factors and prognostic values of non-small cell lung cancer (NSCLC). The expression level of miR-222 in the pathological tissues and paired normal tissues of NSCLC was evaluated using a quantitative real-time RT-PCR. A Kaplan-Meier survival curve was demonstrated following a log-rank test. Results showed that miR-222 expression level is up-regu- lated in NSCLC tissues compared with matched normal tissues (mean ± SD: 3.55 ± 1.71vs. 2.08 ± 1.01, P < 0.001). The high expres- sion of miR-222 in NSCLC cancer tissues was also remarkably related with aggressive clinic pathological features. The expression level of miR-222 was associated with tumor grade (P=0.031) and lymph node metastasis (P = 0.0028). Moreover, the results of Kaplan-Meier analyses indicated that patients with high expression level of microRNA-222 had shorter overall survival and progres- sion free survival (P < 0.001). The multivariate analysis clearly indicated that the high miR-222 expression in biopsy samples might be a useful independent biomarker for NSCLC prognosis (RR 3.23; 95%CI, 2.12–5.47). Our data demonstrated that the aberrant expres- sion of microRNA-222 is associated with NSCLC progression and it might be a potential biomarker for NSCLC prognosis.
microRNA-222, non-small cell lung cancer, progression and prognosis.